TMThomas M. Moehler

Thomas M. Moehler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Thomas M. Moehler has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Thalidomide in Multiple Myeloma

    by T. M. Moehler, J. Hillengass, A. Glasmacher, H. Goldschmidt

    Thalidomide (Thal) has antiangiogenic and immunomodulatory activity. Clinical research provided clear evidence that Thal is one of the most active drugs for the treatment of multiple myeloma leading to decrease of monoclonal protein of at least 50% in 30% of patients with relapsed or refractory multiple myeloma. Randomized trials based on a large body of evidence from phase II trials determined that Thal significantly increases total response rate in combination regimens (dexamethasone [Dex] and or chemotherapy) for relapsed as well as newly diagnosed patients. Thal also decreases time to response in combination therapy approaches. Thal has therefore been recognized by leading organizations as part of the treatment concept for patients with relapsed or refractory disease. Strict guidelines apply for the treatment and monitoring of Thal therapy to prevent the teratogenic effects of Thal and to monitor and prevent other potential adverse events as neuropathy and thrombosis. Additional randomized studies will now define the status of Thal for newly diagnosed patients and will be the basis for the approval in Europe and other countries world wide.


  • Antiangiogenic Therapy in Hematologic Malignancies

    by Moehler T. M., Hillengass J., Goldschmidt H., Ho A. D.

    Angiogenesis is defined as the formation of new capillaries from prexisting blood vessels and plays an important role in the progression of solid tumors and hematologic malignancies. Markers of angiogenesis correlate with clinical characteristics in leukemia and non-Hodgkin´s-lymphoma, serving as predictors of poor prognosis. Antiangiogenic effects of chemotherapeutics as well as of novel drugs such as farnesyltransferase inhibitors and tyrosine kinase inhibitors such as Gleevec(r) might contribute to their therapeutic potential. Thalidomide which has antiangiogenic effects and direct cytotoxic effects was found to be effective in multiple myeloma and is considered as an established treatment modality for patients with refractory or relapsed multiple myeloma. Thalidomide has a significant therapeutic effect in myelodysplastic syndrome (MDS) by improving cytopenia and achieving independence of transfusion therapy in a subset of patients. Preliminary data indicate activity of specific VEGF receptor tyrosine kinase (RTK) inhibitors in multiple myeloma (MM) and acute myeloid leukemia (AML). The positive correlation between increased levels of angiogenic cytokines and clinical response to VEGF-RTK inhibitors and thalidomide indicates the relevance of detecting angiogenesis markers to identify best candidate patients for specific approaches. Including antiangiogenic drugs into treatment protocols for hematologic malignancies is an important task for future clinical studies.


  • Open Access

    Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy

    by Thomas M. Moehler, Kai Neben, Axel Benner, Gerlinde Egerer, Fatime Krasniqi, Anthony D. Ho, Hartmut Goldschmidt

    The feasibility and efficacy of a combination of thalidomide, cyclophosphamide, etoposide, and dexamethasone were studied in 56 patients with poor-prognosis multiple myeloma. Of 50 patients evaluable for response, 4% achieved complete response (CR), 64% partial response (PR), 18% minimal response (MR), 6% stable disease (SD), and 8% progressive disease (PD), resulting in an objective response rate (≥ MR) of 86.0% (76.7% overall objective response rate in intent-to-treat analysis; n = 56). Subsequent to successful remission induction, 18 patients received autologous or allogeneic stem cell transplantation. The median progression-free survival in all patients was 16 months. The median overall survival time could not be calculated, since the last observed death occurred after 16 months of follow-up (median follow-up of 14 months) with a corresponding estimated survival probability of 55%. Severe adverse effects (World Health Organization III/IV) included infectious complications (35.7%) and cardiovascular events (7.1%). The data suggest that Thal improves antitumor activity of salvage chemotherapy regimens in poor-prognosis multiple myeloma.


  • Angiogenesis in hematologic malignancies

    by T. Moehler, K. Neben, A. Ho, H. Goldschmidt

    Angiogenesis defined as the blood vessel generation from preexisting blood vessels was found to play an important role in the progression of solid tumors. In addition, bone marrow-derived endothelial precursor cells may contribute to tumor angiogenesis. Recently angiogenesis induction was described in several hematologic neoplasms as leukemia, lymphoma, myelodysplastic syndrome and multiple myeloma (MM). Clinical angiogenesis research also termed as angiodiagnosis has established the prognostic relevance of markers of angiogenesis e.g., microvessel density and circulating levels of angiogenic peptides. Development of antiangiogenic treatment for hematologic neoplasms has recently been sparked by the success of Thalidomide (Thal) which has antiangiogenic properties in MM. Antiangiogenic treatment strategies are now being tested in clinical trials on several types of hematologic neoplasms.


  • Funktioelle Magnetresonanztomographie in Diagnostik und Therapiemonitoring beim Multiplen Myelom

    by T.M. Moehler, H. Hawighorst, K. Neben, G. Egerer, A. Benner, J. Hillengass, R. Max, A.D. Ho, H. Goldschmidt, G. van Kaick

    Fragestellung. Die semiquantitativen pharmakokinetischen Mikrozirkulationsparameter Amplitude A und Austauschratenkonstante k 21 wurden durch kontrastverstärkte, dynamische Magnetresonanztomographie (d-MRT) beim Multiplen Myelom (MM) vor der Therapie sowie im Therapieverlauf untersucht. Methode. Bei 16 Kontrollpersonen (ktr) und 35 Patienten mit aktivem MM wurde eine d-MRT-Untersuchung der Lendenwirbelsäule und der rechten Spina iliaca posterior superior durchgeführt. Ein aus den pharmakokinetischen Daten berechnetes farbkodiertes Parameterbild wurde auf das statische MRT-Bild projiziert. Ergebnisse. Amplitude A und Austauschratenkonstante k 21 waren bei den Myelompatienten signifikant erhöht und nahmen im Therapieverlauf in 7 von 8 untersuchten Fällen ab [pA ktr =0,2 (0,09–0,4); Median A MM =0,93 (0,2–1,52); Median k 21ktr =0,09 min–1 (0,03–0,9); Median k 21MM =4,57 (0,21–23,8)]. Im farbkodierten Parameterbild wiesen 13 Patienten ein “diffuses” und 22 Patienten ein “fokales” Verteilungsmuster der Mikrozirkulationsparameter auf. Eine Beckenkammhistologie bei 8 Patienten zeigte eine hohe Korrelation zwischen Plasmazellvermehrung und Erhöhung der Mikrozirkulationsparameter. Schlussfolgerungen. Die Darstellung der Mikrozirkulationsveränderung durch d-MRT ist ein für die Diagnostik und Therapiebeurteilung des MM neues bildgebendes Verfahren. Aim of the study. Investigation of the quantitative microcirculation parameters amplitude A and exchange rate constant k 21 determined by contrast-enhanced dynamic magnetic resonance imaging (d-MRI) in multiple myeloma (MM). Methods. d-MRT of lumbar spine and right spina iliaca superior posterior of 16 controls (ctr) and 35 patients with active MM. Generation of colour-coded images of microcirculation parameters superimposed onto static MRI images. Results. Amplitude A and k 21 parameters were significantly increased in patients with MM and down modulated by therapy in 7 of 8 MM cases in a follow-up investigation [pA ctr =0.2 (0.09–0.4); median A MM =0.93 (0.2–1.52); median k 21ctr =0.09 min–1 (0.03–0.9); median k 21MM =4.57 min–1 (0.21–23.8)]. Thirteen patients revealed a “diffuse” and 22 a “focal” pattern of distribution of microcirculation parameters. Bone marrow biopsies in 8 cases revealed an correlation between bone marrow plasma cell infiltration and increased microcirculation parameters. Conclusion. Identification of microcirculation changes by d-MRI is a novel imaging technique for the detection and monitoring of MM bone lesions.